[HTML][HTML] A snapshot of the PD-1/PD-L1 pathway
Cancer cells can evade the attack from host immune systems via hijacking the regulatory
circuits mediated by immune checkpoints. Therefore, reactivating the antitumor immunity by …
circuits mediated by immune checkpoints. Therefore, reactivating the antitumor immunity by …
Flavonoids as an effective sensitizer for anti-cancer therapy: Insights into multi-faceted mechanisms and applicability towards individualized patient profiles
Cost-efficacy of currently applied treatments is an issue in overall cancer management
challenging healthcare and causing tremendous economic burden to societies around the …
challenging healthcare and causing tremendous economic burden to societies around the …
A dual PI3K/HDAC inhibitor induces immunogenic ferroptosis to potentiate cancer immune checkpoint therapy
F Fan, P Liu, R Bao, J Chen, M Zhou, Z Mo, Y Ma, H Liu… - Cancer research, 2021 - AACR
The capacity of targeted anticancer agents to exert immunomodulatory effects provides a
strong rationale to develop novel agents suitable for combinatorial regimens with …
strong rationale to develop novel agents suitable for combinatorial regimens with …
Immune checkpoint inhibitors combined with targeted therapy: the recent advances and future potentials
B Li, J Jin, D Guo, Z Tao, X Hu - Cancers, 2023 - mdpi.com
Simple Summary Immune checkpoint inhibitors (ICIs) are the most mature treatment of
immunotherapy and have changed the mode of cancer treatment. Recent studies showed …
immunotherapy and have changed the mode of cancer treatment. Recent studies showed …
Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy
A Gutwillig, N Santana-Magal, L Farhat-Younis… - Elife, 2022 - elifesciences.org
Despite the remarkable successes of cancer immunotherapies, the majority of patients will
experience only partial response followed by relapse of resistant tumors. While treatment …
experience only partial response followed by relapse of resistant tumors. While treatment …
DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary …
V Sasidharan Nair, H El Salhat, RZ Taha, A John… - Clinical …, 2018 - Springer
Background High expression of immune checkpoints in tumor microenvironment plays
significant roles in inhibiting anti-tumor immunity, which is associated with poor prognosis …
significant roles in inhibiting anti-tumor immunity, which is associated with poor prognosis …
Treatment of metastatic melanoma with a combination of immunotherapies and molecularly targeted therapies
Simple Summary Immunotherapies and molecularly targeted therapies have drastically
changed the therapeutic approach for unresectable advanced or metastatic melanoma. The …
changed the therapeutic approach for unresectable advanced or metastatic melanoma. The …
Everything old is new again: drug repurposing approach for non-small cell lung cancer targeting MAPK signaling pathway
Non-small cell lung cancer (NSCLC) is a prominent subtype of lung carcinoma that accounts
for the majority of cancer-related deaths globally, and it is responsible for about 80% to 85 …
for the majority of cancer-related deaths globally, and it is responsible for about 80% to 85 …
Bifunctional PD-1× αCD3× αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia
M Herrmann, C Krupka, K Deiser… - Blood, The Journal …, 2018 - ashpublications.org
The CD33-targeting bispecific T-cell engager (BiTE) AMG 330 proved to be highly efficient in
mediating cytolysis of acute myeloid leukemia (AML) cells in vitro and in mouse models. Yet …
mediating cytolysis of acute myeloid leukemia (AML) cells in vitro and in mouse models. Yet …
Current insights into combination therapies with MAPK inhibitors and immune checkpoint blockade
The recent development of high-throughput genomics has revolutionized personalized
medicine by identifying key pathways and molecular targets controlling tumor progression …
medicine by identifying key pathways and molecular targets controlling tumor progression …